COVID-19 News & Education
Latest articles from our blog
Media Statement: Labcorp Receives FDA Emergency Use Authorization for First COVID-19 Test to Identify Specific SARS-CoV-2 Lineages
BURLINGTON, N.C., June 14, 2022 — On Friday, June 10, 2022, Labcorp, a global life sciences company, received an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its VirSeq SARS-CoV-2 NGS (next-generation sequencing) Test on the PacBio Sequel II sequencing system.Read more about Media Statement: Labcorp Receives FDA Emergency Use Authorization for First COVID-19 Test to Identify Specific SARS-CoV-2 Lineages
View our latest news about advancements in health science, COVID-19, and more.
Tracking COVID-19 Variants
Labcorp has been regularly tracking variants of the virus throughout the pandemic. The sensitivity of our PCR test is not impacted by these variants. We have been working with the Centers for Disease Control and Prevention (CDC) to provide sequencing of samples of SARS-CoV-2, the virus that causes COVID-19. Our tests remain effective against variants like Omicron and Delta. This is because they are designed to identify segments of the genetic code that are the least likely to mutate. For more information on variants, see our Viral Variation 101 post or read our Guide to Variants.
Total number of samples sequenced
566,000 as of September 30, 2023
Data covers the U.S. including the District of Columbia and Puerto Rico
Labcorp PCR Test performance confirmed
Alpha (B.1.1.7, Q.1-Q.8)
Beta (B.1.351, B.1.351.2, B.1.351.3)
Epsilon (B.1.427, B.1.429)
Gamma (P.1, P.1.1, P.1.2)
Omicron (B.1.1.529, BA.2, BA.4, BA4.6, BA.5, BQ.1, BQ.1.1, XBB.1.5)